Contents
On this page
- Definitions and the size convention
- A functional classification of nano-biomaterials
- Applications of nano-biomaterials
- Characterisation expected by reviewers
- Safety assessment within a risk-management framework
- Required content of the materials and characterisation section
- Current gaps in knowledge
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · Nano-biomaterials
Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements
A nano-biomaterial is a material with a structural feature in the nanometre range, intended for contact with biological systems. The size threshold is a regulatory convention rather than a physical boundary, and the substantive meaning of the term is behavioural: nanoscale features alter surface area, protein adsorption and cellular uptake. Papers in this field are rejected considerably more often for incomplete characterisation than for weak results.
Two distinct entities are described as nanomaterials: a 40 nm particle and a bulk implant with a nanostructured surface. Both usages are legitimate, and conflating them is the most common source of confusion in this literature. The significance of the nanoscale lies not in the dimension itself but in its consequences: a very high specific surface area, a protein corona that forms within seconds of contact with biological fluid, and uptake routes unavailable to larger particles. For these reasons, a nano-biomaterial cannot be described by composition alone, and the characterisation table is typically the first part of the paper that reviewers examine.
Learning objectives
- The working definitions and the 1–100 nm convention, and what the convention does and does not determine
- How nano-biomaterials may be classified usefully by dimensionality and by intended biological role
- Applications in tissue engineering scaffolds, drug delivery, imaging and photothermal therapy
- The characterisation expected by reviewers, including the measurements most frequently omitted
- How safety assessment operates within a risk-management framework, and the nano-specific gaps that remain
- The information that a materials and characterisation section must contain to be reproducible
Common misconceptions
- “The term nanomaterial refers only to nanoparticles.” The term includes nanofibres, nanotubes, nanostructured surfaces and nanocomposites. A bulk implant with nanotopography is a nano-biomaterial, and the report should specify which type is under study.
- “1–100 nm is a physical boundary.” It is a definitional convention. Zheng and colleagues, in RSC Advances, cite the European Commission definition of nanomaterials as materials in which 50% or more of particles have one or more external dimensions in the 1–100 nm range, a threshold set for regulatory practicability rather than because behaviour changes at 100 nm.
- “A mean size and a transmission electron microscopy (TEM) image are sufficient to characterise the material.” Size without a measure of distribution, surface charge, surface chemistry and the dispersion state in the relevant biological medium does not constitute characterisation.
- “The properties of the material as synthesised are those that operate in the body.” This is not the case. A protein corona forms on contact with biological fluid and alters effective size, charge and recognition, so size measured in water is of limited value in predicting behaviour in serum.
- “Biocompatibility is a property of the material.” It is a property of a material in a specific use, for a specific type and duration of contact. ISO 10993-1 and the FDA guidance on its use frame it in this way, as biological evaluation within a risk management process.
Definitions and the size convention
A nano-biomaterial is a material with at least one structural feature in the nanometre range, designed or used in contact with biological systems. Hasirci and colleagues, in the Journal of Biomaterials Science, Polymer Edition, gave an early systematic account of the field and framed it in these terms: the nanoscale feature is the defining characteristic, whether it belongs to a discrete particle or to the surface of a bulk device 26.
The quantitative convention most often cited comes from the European Commission, as reported by Zheng and colleagues in RSC Advances: a nanomaterial is one in which 50% or more of the particles, in a number-based size distribution, have one or more external dimensions in the 1–100 nm range 16. Two features of that definition are relevant to reporting. It is number-based, so a mass-based or intensity-based size distribution does not address it; dynamic light scattering (DLS) reports intensity-weighted size, which is why DLS alone cannot establish that a material meets the definition 16. It is also a threshold for classification, not a claim that behaviour changes at 100 nm; a 120 nm liposome behaves far more like a 90 nm one than like a 2 micrometre particle.
The properties that change at the nanoscale are few. Specific surface area rises steeply as size decreases, so surface chemistry dominates behaviour 26. Mechanical and optical properties can depart from bulk values. Cellular uptake routes that are closed to larger particles become available. Biological fluids also deposit a protein corona within seconds, and this corona becomes the surface that the body encounters.
A functional classification of nano-biomaterials
Taxonomies in this field are usually based on chemistry (metallic, ceramic, polymeric, carbon-based), which is convenient but of limited predictive value. Two cross-cutting classifications are more informative: dimensionality, because it determines which measurements apply, and intended biological role, because it determines which safety questions are relevant.
Dimensionality separates discrete nanoparticles (measured by size distribution, zeta potential, morphology) from nanofibres and nanotubes (measured by diameter, length and aspect ratio, where aspect ratio is itself a toxicological concern) from nanostructured surfaces (measured by topography, roughness and feature spacing, with no particle size to report at all) from nanocomposites (where dispersion within the matrix and the risk of release are the questions). Reporting zeta potential for a nanostructured titanium surface is a category error; reporting feature spacing for a drug-loaded micelle is another.
Role distinguishes materials intended to be taken up by cells from those intended not to be, and materials intended to degrade from those intended to persist. These two axes largely determine the safety testing programme, which is why the classification table below is organised around them.
Nano-biomaterials by dimensionality: required measurements and justifications
| Form | Examples | Measurements that apply | The question reviewers ask |
|---|---|---|---|
| Discrete nanoparticles | Metal and metal-oxide particles, polymeric micelles, liposomes, lipid nanoparticles, quantum dots | Number-based size distribution with PDI; zeta potential with medium, pH and ionic strength; morphology by TEM or SEM; surface chemistry; encapsulation efficiency with separation method | What was the agglomeration state in the actual test medium, and which dose metric is being reported? |
| Nanofibres and nanotubes | Electrospun scaffolds, carbon nanotubes, nanocellulose | Diameter and length distributions; aspect ratio; alignment; porosity and pore-size distribution; mechanical properties of the mat | Does the aspect ratio raise a fibre-specific hazard concern that read-across from a spherical particle cannot address? |
| Nanostructured surfaces | Nanotopographed titanium, anodised or etched implant surfaces, nanopatterned culture substrates | Topography and feature dimensions by AFM or SEM; roughness parameters; wettability; surface composition by XPS; sterilisation effect on the surface | Was the topography preserved through sterilisation and after protein adsorption, and was it re-measured? |
| Nanocomposites | Hydroxyapatite-filled polymers, graphene oxide composites, clay-reinforced matrices | Filler loading and dispersion within the matrix; interfacial bonding; bulk mechanical properties; release or shedding of filler on degradation or wear | Can the nanoscale filler be released during use or degradation, and was that tested? |
Compiled from the sources cited on this page: Hasirci and colleagues in the Journal of Biomaterials Science, Polymer Edition; Zheng and colleagues in RSC Advances; Kumar and Abrahamse in the International Journal of Molecular Sciences; Tang and colleagues in Progress in Polymer Science; and Al-Zyoud and colleagues in Materials on biocompatibility characterisation. A reporting guide, not a standard.
Applications of nano-biomaterials
Tissue engineering. Zheng and colleagues, in RSC Advances, review nanomaterials in tissue engineering, where nanofibrous scaffolds approximate the dimensions of native extracellular matrix and nanoscale topography influences cell adhesion and differentiation 16. Kumar and Abrahamse, in the International Journal of Molecular Sciences, review nanobiomaterials used to deliver natural compounds for tissue engineering, and Tang and colleagues, in Progress in Polymer Science, cover polymeric nanostructured materials for biomedical applications generally 19,24.
Drug delivery. Liu and colleagues, in Chinese Chemical Letters, review nanoparticle delivery systems for diagnosis and treatment, and Zheng and colleagues survey polymeric nanomicelles that have reached clinical trials or the market 13,15. Encapsulation efficiency is the attribute most frequently reported, and most frequently reported without its method: Zheng and colleagues note that emulsion diffusion typically gives about 70% encapsulation efficiency, which is a useful benchmark precisely because many papers report a figure without stating how free and encapsulated drug were separated.
Imaging and theranostics. Nanoparticulate contrast and reporter systems lie at the interface with device technology; Metuh, Petersen and Ou, in Laser & Photonics Reviews, review wireless optoelectronic biomedical implants, and our page on applications of optoelectronic devices covers the detection side. Where a nanocarrier is being chosen to deliver a drug substance, the decision belongs with applications of active pharmaceutical ingredients and material selection for drug development.
Photothermal and photodynamic therapy. Graphene oxide and reduced graphene oxide nanocomposites convert near-infrared light to heat; Zheng and colleagues report photothermal therapy performed at a power density of 0.15 W/cm² 16. The reporting principle generalises: an optical therapy result reported without the power density, the wavelength and the exposure duration cannot be compared with other results.
Source: Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058.
Characterisation expected by reviewers
This is the section in which nano-biomaterials papers most often fail, and the failures are predictable. For a particulate material, the expected set comprises: size as a distribution with a polydispersity measure and the technique named; morphology by electron microscopy with the preparation method stated; surface charge as zeta potential with the medium, pH and ionic strength given, because zeta potential measured in water is not transferable; surface chemistry by a technique capable of detecting it, such as XPS or FTIR; crystallinity where relevant; purity and residual synthesis reagents, especially surfactants and reducing agents, which are frequently the actual source of an observed cytotoxicity; and endotoxin, which is a common uncontrolled confounder in cell-based work.
Two measurements are absent from most submitted manuscripts and are requested by most careful reviewers. The first is the dispersion state in the biological medium actually used: a material that is monodisperse in water and aggregated in serum-containing culture medium is being tested as aggregates, irrespective of what the characterisation table reports. Size and polydispersity should be reported in the test medium, at the test concentration and temperature, at the start and end of exposure. The second is the dose metric. Mass per volume is conventional and poorly related to effect; surface area per volume and particle number per cell often correlate better, and reporting more than one allows a reader to compare the result with studies that used different metrics.
Al-Zyoud and colleagues, in Materials, set out biocompatibility testing for implants as a characterisation and selection problem rather than a pass-or-fail gate, which is the appropriate framing for this section of a paper 9.
Safety assessment within a risk-management framework
Biological evaluation of a material in contact with the body is organised by ISO 10993-1, and the FDA’s guidance on the use of that standard makes the governing logic explicit: evaluation is conducted within a risk management process, driven by the nature and duration of body contact, and existing data should be used where adequate rather than tests being repeated by default 1. The tests follow from the contact category, not from the material’s novelty.
Contact duration is the main driver. Al-Zyoud and colleagues, in Materials, note that biodegradation testing is considered essential when a device, including a nanostructured one, is intended for implantation exceeding 30 days 9. For a degradable nano-biomaterial, that threshold marks the point at which degradation products become part of the safety argument rather than a footnote, and the degradation products of a nanomaterial may themselves be nanoscale.
Three nano-specific complications should be addressed in a manuscript. Standard cytotoxicity assays may be subject to interference from the material itself, since nanoparticles adsorb assay dyes and scatter light, so an interference control is required rather than optional. The protein corona means that the entity reaching the cell is not the entity that was synthesised 13,26. In addition, high-aspect-ratio fibres and tubes raise a distinct mechanistic concern that a spherical particle of the same chemistry does not, so chemistry-based read-across between morphologies is not defensible 26.
The broader regulatory environment for devices illustrates the cost of weak evidence. Kadakia and colleagues, in JAMA, examined the use of recalled devices as predicates in new authorisations under the 510(k) pathway and subsequent recall risk; Everhart and colleagues, in the same journal, examined the association between regulatory submission characteristics and recalls among 510(k)-cleared devices 12. Our page on material selection for medical devices covers the selection decision in that context.
Safety evidence by contact type and duration, within a risk-management framework
| Contact situation | What drives the evidence requirement | Nano-specific addition |
|---|---|---|
| Surface contact, limited duration | Nature of the contacting tissue and exposure time, per ISO 10993-1 as applied within risk management | Whether nanoscale features or particles can detach during use |
| External communicating or short-term implant | Contact category and duration determine the biological endpoints to be addressed | Agglomeration state in the contacting fluid; interference controls for cytotoxicity assays |
| Implant exceeding 30 days | Longer contact brings degradation and systemic distribution into scope; Al-Zyoud and colleagues treat biodegradation testing as essential beyond this duration | Degradation products may themselves be nanoscale, and their fate is usually unstudied |
| Intended cellular uptake (delivery, imaging) | The material is designed to enter cells, so distribution, clearance and intracellular persistence are part of the argument | Protein corona changes the entity that reaches the cell; mass dose correlates poorly with effect |
| High aspect ratio forms | Form rather than chemistry drives part of the concern | Read-across from a spherical particle of the same composition is not defensible |
Framework as set out in ISO 10993-1 and the FDA guidance on its use, which direct that biological evaluation be conducted within a risk management process driven by the nature and duration of body contact. The 30-day biodegradation threshold is as stated by Al-Zyoud and colleagues in Materials. The nano-specific column reflects the mechanistic concerns described in the reviews cited on this page.
Required content of the materials and characterisation section
A nano-biomaterials methods section must make three things recoverable: what the material was, what state it was in when it encountered the biological system, and how this is known. Most drafts address the first partially and the second not at all. The minimum comprises the synthesis or source with the reagents and their grades, the characterisation set described above with techniques named, the complete dispersion protocol (medium, sonication energy and duration, stabiliser, and interval between dispersion and exposure) and the characterisation repeated in the test medium.
The dispersion protocol warrants particular emphasis because it is treated as trivial although it is not. Sonication energy, probe versus bath sonication, and whether the suspension was used immediately or after an hour all alter the agglomeration state, and therefore the dose that reaches cells. Two laboratories using the same powder with different dispersion protocols are testing different materials. The example below contrasts a typical paragraph with a reproducible one.
A nanoparticle materials and exposure paragraph: typical and reproducible versions
Not reproducible
Silver nanoparticles of approximately 40 nm were synthesised by chemical reduction and characterised by TEM and DLS. Nanoparticles were dispersed in culture medium and added to cells at concentrations of 1 to 100 micrograms per millilitre. Cell viability was assessed by MTT assay after 24 h.
What state were the particles in when they met the cells? Characterised in water but dosed in serum-containing medium, where agglomeration is expected, so the material to which cells were exposed is unknown.
What was the dispersion protocol? No sonication parameters or timing are reported, so another laboratory cannot reproduce the same agglomeration state.
Zeta potential in what? Not reported at all; a value measured in water would not, in any case, transfer to the test medium.
Was residual reductant removed? Not addressed, although residual synthesis reagents are a common actual source of apparent cytotoxicity.
Does the assay interfere? Nanoparticles adsorb dyes and scatter light; without an interference control, the viability values may be partly artefactual.
Which dose metric? Mass per volume only, which correlates poorly with effect and cannot be compared with studies using other metrics.
Reproducible
Silver nanoparticles were synthesised by borohydride reduction of silver nitrate (99.9999% trace metals basis) in the presence of 0.3 mM trisodium citrate, then purified by three cycles of centrifugation and resuspension in ultrapure water to remove residual reductant; residual borohydride was below the detection limit of the iodometric method used. The number-based size distribution by TEM over 312 particles gave a mean core diameter of 38 nm with a standard deviation of 6 nm; hydrodynamic diameter in ultrapure water was 47 nm with a polydispersity index of 0.09 by DLS. Zeta potential was minus 34 mV in 10 mM HEPES at pH 7.4 and an ionic strength of 10 mM. Surface composition was confirmed by XPS as citrate-capped metallic silver with no detectable oxide. Endotoxin was below 0.05 EU/mL by LAL assay. For exposure, stock suspension was diluted directly into DMEM containing 10% fetal bovine serum, bath-sonicated for 2 min at 40 kHz and used within 10 min. In that medium the hydrodynamic diameter was 119 nm with a polydispersity index of 0.31 at the start of exposure and 164 nm at 24 h, so cells were exposed to agglomerates rather than primary particles. Doses are reported as 1 to 100 micrograms per millilitre and additionally as particle number per cell (1.2 x 10^3 to 1.2 x 10^5) and as surface area per well. MTT absorbance was corrected using a nanoparticle-only interference control at each concentration, which accounted for up to 8% of raw signal at the highest dose.
Size is given as a number-based distribution by TEM, which is what the definitional threshold requires, alongside an intensity-based hydrodynamic measure.
Characterisation is repeated in the actual test medium at the start and the end of exposure, and the conclusion — agglomerates, not primary particles — is stated rather than left for the reader to infer.
The dispersion protocol is specified to sonication frequency, duration and time-to-use, so the agglomeration state is reproducible.
A justified acceptance limit is established for the residual reductant, removing the most common alternative explanation for cytotoxicity.
Zeta potential carries its medium, pH and ionic strength, which is what makes the value meaningful.
An interference control is reported with its magnitude, and three dose metrics are given so the result can be compared across studies.
The second version requires approximately one additional afternoon of measurements and removes six separate grounds on which a reviewer could reject the paper. It also changes the finding: once agglomeration in the medium is reported, the study concerns 119 nm agglomerates, which is a different and more accurate claim than one concerning 40 nm particles.
Current gaps in knowledge
The question of dose metric remains unresolved. No source cited here establishes which metric (mass, surface area or particle number) best predicts biological effect across material types, and the appropriate response is to report more than one rather than to assert that one is correct.
In vitro to in vivo extrapolation for nanomaterials is weak. Static cell culture exposes cells to a settling, agglomerating suspension at a concentration that differs from the concentration a tissue would experience, and none of the sources cited here offers a validated scaling relationship. Cell-based results should therefore be presented as mechanistic rather than predictive.
Long-term fate after degradation remains largely unstudied for most systems. Al-Zyoud and colleagues identify biodegradation testing as essential beyond 30 days of implantation, which acknowledges that the question matters but does not answer it 9. Where the material degrades, authors should state what was measured and over what period, and should state explicitly what was not followed up.
Finally, standardisation remains limited. Characterisation methods are not harmonised across laboratories in the way that compendial methods are for excipients and active pharmaceutical ingredients, which largely accounts for the poor reproducibility of results in this field. The practical response is to report method detail in full rather than to cite a technique by name alone. The concepts and definitions hub and our page on bio-macromolecules cover the neighbouring terms, since biological assemblies occupy the same size regime.
Key points
Key points
A nano-biomaterial is a material with a nanoscale structural feature intended for biological contact, and the 1–100 nm convention (50% or more of particles by number, in the European Commission definition reported by Zheng and colleagues) is a classification threshold rather than a physical boundary. The relevant considerations are the consequences of the nanoscale: high surface area, a protein corona that forms immediately in biological fluid, and uptake routes unavailable to larger particles. Characterisation should reflect these properties and should be performed in the medium used experimentally, because a material that agglomerates in serum is tested as agglomerates. Safety assessment follows the ISO 10993-1 logic of contact type and duration within a risk-management process, with biodegradation testing treated as essential beyond 30 days of implantation.
Application to your study
Application to your study
- The type of nano-biomaterial should be specified. Whether the material is a particle, fibre, surface or composite determines which measurements are applicable.
- Size should be reported as a number-based distribution rather than a mean. The technique should be named; dynamic light scattering (DLS) reports intensity-weighted size and cannot by itself establish that the material meets the definitional threshold.
- Zeta potential should be reported with the medium, pH and ionic strength. A value reported without these parameters cannot be applied to any other condition.
- The material should be characterised in the biological medium used, at the start and end of exposure. The report should then state what the cells or tissue were exposed to.
- The dispersion protocol should be reported in full. This includes medium, sonication type and energy, duration, stabiliser and the interval between dispersion and exposure.
- Justified acceptance limits should be established for endotoxin and residual synthesis reagents, as applicable to the material and its intended use. Surfactants, reducing agents and endotoxin are frequently the actual cause of an observed effect.
- An assay interference control should be performed and reported. Nanoparticle-only wells should be included at every concentration, with the magnitude of interference stated.
- At least two dose metrics should be reported. Mass per volume should be reported together with particle number per cell or surface area per volume, so that results can be compared across studies.
- Safety evidence should be matched to the type and duration of contact rather than to the novelty of the material. The ISO 10993-1 risk-management logic should be followed, with a statement of which endpoints were addressed using existing data.
- If the material degrades and will be implanted for more than 30 days, degradation products should be addressed explicitly. The report should state what was measured, over what period, and what was not followed up.
Frequently asked questions
The most cited convention is the European Commission definition, reported by Zheng and colleagues in RSC Advances: a material in which 50% or more of the particles, in a number-based size distribution, have one or more external dimensions in the 1–100 nm range. Two implications follow. It is number-based, so an intensity-weighted measurement such as dynamic light scattering cannot by itself establish compliance, whereas electron microscopy over a counted population can. It is also a classification threshold rather than a physical boundary: nothing fundamental changes at 100 nm, and a 120 nm liposome behaves much more like a 90 nm one than like a micron-scale particle. The threshold is therefore best regarded as a regulatory convention, and the behaviour as the scientific question.
For a particulate material: a number-based size distribution with a polydispersity measure and the technique named; morphology by electron microscopy with the preparation stated; zeta potential with medium, pH and ionic strength; surface chemistry by XPS or FTIR; crystallinity where relevant; and justified acceptance limits for endotoxin and residual synthesis reagents, as applicable to the material and its intended use. In addition, the two items most often omitted should be reported: size and polydispersity in the actual biological test medium at the start and end of exposure, and more than one dose metric. For fibres, length and aspect ratio distributions should be added; for surfaces, topography and roughness with the effect of sterilisation; for composites, filler dispersion and whether filler can be released.
The protein corona changes the entity that interacts with cells. Within seconds of entering a biological fluid, a nanomaterial adsorbs a layer of proteins that alters its effective size, surface charge and the receptors that recognise it. The practical consequence is that characterisation performed in water or buffer describes a material that no longer exists once the experiment starts. This is why size and polydispersity should be re-measured in the serum-containing medium at the test concentration and temperature, and why a result should be described in terms of what was actually present — often agglomerates of a few hundred nanometres rather than the primary particles named in the title.
Through biological evaluation within a risk management process, as set out in ISO 10993-1 and the FDA’s guidance on the use of that standard. The endpoints follow from the nature and duration of body contact rather than from the material’s novelty, and existing adequate data should be used rather than tests repeated by default. Duration is the main driver: Al-Zyoud and colleagues, in Materials, treat biodegradation testing as essential when a device, including a nanostructured one, is intended for implantation exceeding 30 days. The nano-specific items should also be addressed: interference controls for cytotoxicity assays, the agglomeration state in the contacting fluid, and the avoidance of chemistry-based read-across between a fibre and a sphere.
The sources cited here do not resolve this question. Mass per volume is conventional and correlates poorly with biological effect, because for the same mass a smaller particle presents far more surface and far more particles. Surface area per volume and particle number per cell often track effect better, but no source establishes a general rule across material types. The defensible practice is to report at least two metrics — conventionally mass plus one of the others — and to give enough characterisation data, size distribution and density, that a reader can convert to a third. This makes the result comparable with studies that used different metrics.
Such a comparison is valid only if both papers state how free and encapsulated material were separated, which many do not. Zheng and colleagues, in RSC Advances, note that emulsion diffusion typically gives about 70% encapsulation efficiency, which provides a reasonable benchmark for that method. However, the value depends heavily on the separation step (ultrafiltration, dialysis, size-exclusion or ultracentrifugation), because each recovers a different fraction of loosely associated payload, and on whether the calculation is against the drug added or the drug recovered. The separation method, the calculation basis and the mass balance should be reported; an efficiency figure without these three items cannot be meaningfully compared.
Yes, and sufficiently often that an interference control should be treated as mandatory rather than as good practice. Nanoparticles adsorb assay dyes and their reduction products, scatter and absorb light at the read wavelength, and can react directly with assay reagents. The consequence is viability values that are partly artefactual, in either direction. The control is straightforward: nanoparticle-only wells without cells, at every concentration tested, read under the same conditions, with the magnitude of the interference reported rather than silently subtracted. Where interference is substantial, a second assay with a different readout, such as a membrane-integrity or ATP-based measure, provides the necessary orthogonal confirmation.
Reproducibility is lower than it should be, and the reasons are mostly methodological rather than scientific. Characterisation methods are not harmonised across laboratories in the way compendial methods are for excipients and drug substances, dispersion protocols are frequently omitted although they determine agglomeration state, dose metrics differ between papers without conversion data, and assay interference is often uncontrolled. Each of these can readily be addressed within a single paper. The practical response is to report method detail comprehensively (sonication energy and duration, medium composition, time to exposure, counted particle numbers for size distributions) rather than to name a technique and leave the parameters implied.
References
- U.S. Food and Drug Administration (CDRH, CBER). Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". U.S. Food and Drug Administration. 2023. read 9 October 2026. fda.gov
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
- Huang Y, Liu H, Lin Y, Hu J, Zou L, Chen S, Chen O, Yi X, Wang L. Micro-LEDs in biomedicine: from implantable optogenetics to intelligent theranostics. Journal of Semiconductors. 2026;47(8):081606. doi:10.1088/1674-4926/26050037 read 9 October 2026. doi.org/10.1088/1674-4926/26050037
- Cho EH, Kim YW, Sim J, Yeon H, Baek S, Jeong SM, Lee J, Jeon Y, Choi KC. Recent advances in flexible and wearable OLEDs for biomedical applications: a review. Materials Horizons. 2025. doi:10.1039/D5MH00742A read 9 October 2026. doi.org/10.1039/D5MH00742A
- Daniel SA, Suya Prem Anand P, Jesuarockiam N, Tabrej K, Shabir Hussain K. Advancement in biomedical implant materials-a mini review. Frontiers in Bioengineering and Biotechnology. 2024;12. doi:10.3389/fbioe.2024.1400918 read 9 October 2026. doi.org/10.3389/fbioe.2024.1400918
- Metuh P, Petersen PM, Ou Y. Recent Advances in Wireless Optoelectronic Biomedical Implants. Laser & Photonics Reviews. 2024;18(12):2300752. doi:10.1002/lpor.202300752 read 9 October 2026. doi.org/10.1002/lpor.202300752
- Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
- Al-Zyoud W, Haddadin D, Hasan SA, Jaradat H, Kanoun O. Biocompatibility Testing for Implants: A Novel Tool for Selection and Characterization. Materials. 2023;16(21):6881. doi:10.3390/ma16216881 read 9 October 2026. doi.org/10.3390/ma16216881
- Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
- Wu W, Wang L, Shen G. Flexible photoplethysmographic sensing devices for intelligent medical treatment. Journal of Materials Chemistry C. 2023;11:97-112. doi:10.1039/D2TC03318F read 9 October 2026. doi.org/10.1039/D2TC03318F
- Kadakia KT, Dhruva SS, Caraballo C, et al. Use of recalled devices in new device authorizations under the US Food and Drug Administration's 510(k) pathway and risk of subsequent recalls. JAMA. 2023;329:136-143. read 9 October 2026. tctmd.com
- Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters. 2022. doi:10.1016/j.cclet.2022.05.032 read 9 October 2026. doi.org/10.1016/j.cclet.2022.05.032
- Zhao H. Optogenetic Implants. Handbook of Biochips. 2022:179-206. doi:10.1007/978-1-4614-3447-4_48 read 9 October 2026. doi.org/10.1007/978-1-4614-3447-4_48
- Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, Wang C. An overview of polymeric nanomicelles in clinical trials and on the market. Chinese Chemical Letters. 2021;32(1):243-257. doi:10.1016/j.cclet.2020.11.029 read 9 October 2026. doi.org/10.1016/j.cclet.2020.11.029
- Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058. doi:10.1039/d1ra01849c read 9 October 2026. doi.org/10.1039/d1ra01849c
- Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
- Lee I, Park N, Lee H, Hwang C, Kim JH, Park S. Systematic Review on Human Skin-Compatible Wearable Photoplethysmography Sensors. Applied Sciences. 2021;11(5):2313. doi:10.3390/app11052313 read 9 October 2026. doi.org/10.3390/app11052313
- Kumar SSD, Abrahamse H. Advancement of nanobiomaterials to deliver natural compounds for tissue engineering applications. International Journal of Molecular Sciences. 2020;21(18):1-27. doi:10.3390/ijms21186752 read 9 October 2026. doi.org/10.3390/ijms21186752
- Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
- Kang CW, Fang FZ. State of the art of bioimplants manufacturing: part I. Advances in Manufacturing. 2018;6:20-40. doi:10.1007/s40436-017-0207-4 read 9 October 2026. doi.org/10.1007/s40436-017-0207-4
- Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
- Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B, Chen X. Polymeric nanostructured materials for biomedical applications. Progress in Polymer Science. 2016;60:86-128. doi:10.1016/j.progpolymsci.2016.05.005 read 9 October 2026. doi.org/10.1016/j.progpolymsci.2016.05.005
- Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
- Hasirci V, Vrana E, Zorlutuna P, Ndreu A, Yilgor P, Basmanav FB, Aydin E. Nanobiomaterials: a review of the existing science and technology, and new approaches. Journal of Biomaterials Science, Polymer Edition. 2006;17(11):1241-1268. doi:10.1163/156856206778667442 read 9 October 2026. doi.org/10.1163/156856206778667442
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements. Pubrica. https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/
Pubrica Academy. “Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/.
Pubrica Academy (2026) Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/ (Accessed: 15 October 2026).
Pubrica Academy. “Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/
Pubrica Academy, ‘Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/> accessed 15 October 2026.
Pubrica Academy. Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/
Pubrica Academy, “Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/
@misc{what_are_nano_biomaterials_2026,
author = {{Pubrica Academy}},
title = {Nano-Biomaterials: Size Definitions, Applications and Characterisation Requirements},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/what-are-nano-biomaterials/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Nano-biomaterial characterisation and exposure block
This checklist should be completed before the materials section is written. The dispersion and test-medium rows are those most often left blank and most often queried; they also determine whether another laboratory is testing the same material.
NANO-BIOMATERIAL CHARACTERISATION AND EXPOSURE BLOCK
Form: [ ] discrete particles [ ] fibres / tubes [ ] nanostructured surface
[ ] nanocomposite
Intended role: [ ] cellular uptake intended [ ] uptake NOT intended
[ ] degradable [ ] intended to persist
Contact type and duration (ISO 10993-1 categories): ______________________
1. SOURCE OR SYNTHESIS
[ ] Purchased Supplier ____________ Lot ____________ Stated size ______
[ ] Synthesised in-house
Route ........................... ______________________________
Reagents and grades ............. ______________________________
Purification .................... ______________________________
Residual reagent acceptance limits justified? ....... ______ by ______________
2. PRIMARY CHARACTERISATION (as-prepared)
Size, number-based distribution .... mean ______ SD ______
Technique ______________ Particles counted ______
Hydrodynamic size (DLS) ............ ______ nm PDI ______
Medium ______________
Morphology ......................... technique ____________
Sample preparation ______________________________
Zeta potential ..................... ______ mV
Medium ____________ pH ______ Ionic strength ______
Surface chemistry .................. technique ____________
Result ______________________________
Crystallinity (if relevant) ........ ______________________________
Specific surface area .............. ______ m2/g by ____________
Endotoxin .......................... ______ EU/mL by ____________
For fibres / tubes: diameter ______ length ______ aspect ratio ______
For surfaces: feature size ______ roughness (Ra / Sa) ______
preserved after sterilisation? [ ] re-measured
For composites: filler loading ______ dispersion assessed by ______
release / shedding tested? [ ] yes [ ] no
3. DISPERSION PROTOCOL (write this out in full; do not summarise)
Dispersion medium, full composition ______________________________
Stabiliser / pre-wetting agent ..... ______________________________
Sonication: [ ] bath [ ] probe Frequency ______ Power ______
Duration ______ Temperature control ______________
Time between dispersion and exposure ______________
Stock concentration ................ ______________
4. CHARACTERISATION IN THE TEST MEDIUM (the state the biology actually saw)
Medium as used, including serum ..... ______________________________
Hydrodynamic size at t = 0 ......... ______ nm PDI ______
Hydrodynamic size at end of exposure ______ nm PDI ______
Conclusion stated in the text: cells were exposed to ______________
[ ] primary particles [ ] agglomerates of ______ nm
5. DOSE METRICS (report at least two)
Mass per volume .................... ______________
Particle number per cell ........... ______________
Surface area per volume or per well ______________
Conversion data given (size distribution + density)? [ ] yes
6. ASSAY CONTROLS
[ ] Nanoparticle-only interference control at every concentration
Interference magnitude ......... ______ % of raw signal at highest dose
[ ] Second assay with a different readout
[ ] Vehicle / stabiliser-only control
[ ] Positive control
7. SAFETY AND DEGRADATION
Endpoints addressed, and with what ______________________________
[ ] existing adequate data used (cite) [ ] new testing
Implantation duration intended ..... ______ days
If more than 30 days: biodegradation testing addressed? [ ] yes
Degradation products identified .... ______________________________
Follow-up period actually covered .. ______________
What was NOT followed, stated in the discussion: ______________
8. WHAT NOT TO CLAIM
[ ] No in vivo prediction from static cell culture results
[ ] No read-across between fibre and spherical forms of the same chemistry
[ ] No claim that the material meets a number-based size definition on DLS alone Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s medical writing and regulatory writing teams prepare nano-biomaterials methods sections to the standard expected in peer review, including number-based size distributions, zeta potential with its medium, the complete dispersion protocol, characterisation repeated in the biological medium, reported interference controls and more than one dose metric. The team also aligns the safety narrative with the ISO 10993-1 logic of contact type and duration rather than presenting a list of tests, and identifies where a claim exceeds what the characterisation supports.